Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

Netherlands Heart Journal

Volumn 19, Issue 2, 2011, Pages 61-67

  van Nooten, F ^a   Davies, G M ^b   Jukema, J W ^c   Liem, A H ^d   Yap, E ^e   Hu, X H ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Admiraal de Ruyter Hospital   (Netherlands)

^e Merck and Co Inc ^*  (Netherlands)

Author keywords

Cost effectiveness; Ezetimibe; Hypercholesterolaemia

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TREATMENT DURATION;

EID: 79955432579     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-010-0061-5     Document Type: Article

References (34)

1. Allender S, Scarborough P, Peto V. European Cardiovascular Statistics. Oxford: European Health Network; 2008.
2. Molina JA, Heng BH. Global trends in cardiology and cardiothoracic surgery-an opportunity or a threat? Ann Acad Med Singapore. 2009;38(6):541-5.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326 (7404):1423.
4. Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diab Obes. 2009;16(2):183-8.
5. Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J. 2008;29 (7):849-58.
6. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79(5):620-9.
7. Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf. 2009;8(6):715-25.
8. Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008;24(10):2953-66.
9. Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/ simvastatin 10/40 mg compared to doubling the dose of low-,medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology. 2009;113(2):89-97.
10. Perkerson KA, Gillespie EL, Coleman CI. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe. Conn Med. 2005;69(1):19-22.
11. Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin. 2008;24(3):685-94.
12. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62(4):539-54.
13. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-the IN-CROSS study. Int J Clin Pract. 2009;63(4):547-59.
14. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198-205.
15. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-56.
16. Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics. 2004;22 Suppl 3:49-61.
17. Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics. 2004;22 Suppl 3:37-48.
18. Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815-30.
19. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (heterozygous-familial and non-familial) hypercholesterolaemia. NICE Technology Appraisal Guidance 132. [http://www.nice.org.uk/nicemedia/live/11886/38213/38213.doc] Accessed on 18 Jun 2010
20. Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther. 2008;30(8):1508-23.
21. Soini EJ, Davies G, Martikainen JA, et al. Population-based healtheconomic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin. 2010;26(1):25-36.
22. Westert GP, van den Berg MJ, Koolman X, et al. Dutch Health Care Performance Report. Bilthoven, the Netherlands: National Institute for Public Health and the Environment. [http://www.rivm.nl/vtv/object_binary/o6118_Dutch%20Healthcare%20Performance%20Report%202008.pdf] Accessed 11 Jun 2010
23. Dutch Ministry of Foreign Affairs: Welcome to the Netherlands: Health Care. 2009.
24. D'Agostino Sr RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272-81.
25. D'Agostino Sr RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-7.
26. Oostenbrink J. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. CVZ 2005.
27. Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117(22):2875-83.
28. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J. 2001;22(9):751-61.
29. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.
30. College van Zorgverzekeraars: Handboek voor kostenonderzoek 2004 van het College van Zorgverzekeraars. 2009.
31. Nederlands Zorgautoriteit: Tarieflijst zorginstellingen 2009 from the Nederlands Zorgautoriteit. 2009. 32. Z-index, taxe February 2009.
32. Busschbach J, Rabin R, De Charro F, Proceedings of the 24th Scientific Plenary Meeting of the EuroQol Group. Kijkduin. In EuroQoL: The Hague, the Netherlands; 2007.
33. Lamers LM, Stalmeier PF, McDonnell J, et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574-8.
34. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705-9.